Complete session 1

Diversity issues from the perspective of heakth technology assessment – Carole Longson (NICE, UK)

Patient Perspective – Gilliosa Spurrier Bernard (MelanomeFrance; MPNE, FR)

Reflections on how to ensure diversity in clinical practice and clinical trials – Marie von Lilienfeld-Toal (University of Jena, DE)

Ensuring data diversity in big data platforms and building AI algorithms – David Cahané (Owkin, FR) 

Panel Discussion

Complete session 2

Workshop on Measurable Residual Disease (MRD) and Circulating Tumour Nicleotides (ctDNA) in oncology drug development – Axel Glasmacher (CDDF, DE)

Workshop on patient access and engagement in oncology drug development – Mark Lawler (CDDF, UK)

Workshop on histology independent drug development – Ruth Plummer (CDDF, UK)

AAADV-ASCO-CDDF joint workshop on global collaboration – Kim H. Lyerly (AAADV, US)

The complete session 3 cannot be published because one of the speakers did not consent to have his recording shared.

Industry perspective – Theresa Kolben (Bayer, DE) 

Biologist perspective – Steve Wedge (Newcastle University, UK) – This speaker did not consent to have his lecture recording shared

Clinician perspective – Stefan Symeonides (CDDF, UK)

Patient perspective – Bettina Ryll (Melanoma Patient Network Europe, SE)

Panel Discussion

Complete session 4

Medicine trials in 2050: In-clinic or decentral – Jaap Verweij (CDDF, NL)

Process of decentralised clinical trials – Jeff Evans (Glasgow Experimental Cancer Medicine Center, UK)

Industry perspective – Victoria Chiou (AstraZeneca, US)

Panel Discussion

Complete session 5

FDA Project Optimus – Mirat Shah (FDA, US)

The EMA Cancer Medicine Forum and dose optimisation – Denis Lacombe ( EORTC, BE)

The Optimal Cancer Care Alliance (OCCA) view and experience – Daniel Goldstein (Davidoff Cancer Center, Rabin Medical Center, IL)

De-escalation of immunotherapy. The example of MOIO phase III clinical trial – Gwenaelle Gravis (Institut Paoli-Calmettes, FR)

Panel Discussion and closing remarks